Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Looking for weight loss options? GLP-1 agonist medications ... obesity or weight-related conditions, those who took Wegovy lost an average of 35 pounds (14.9% of their body weight), compared ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Similar findings also are possible for the new wave of anti-obesity drugs like Wegovy and Zepbound, given that they provide an average weight loss of 15% to 20%, researchers stated. People with ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

THEY'RE ADVERTISED AS OZEMPIC OR WEGOVY. 12;40;15;00 ... Studies show popular weight loss drugs can benefit heart disease patientsA Phase 3 clinical trial found that injections of the semaglutide ...

Similar findings also are possible for the new wave of anti-obesity drugs like Wegovy and Zepbound, given that they provide an average weight loss of 15% to 20%, researchers stated. People with ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...